Clinical trials: Plasma Cell Tumor
Smoldering Plasma Cell Myeloma
Pembrolizumab in Treating Patients With Intermediate or High-Risk Smoldering Multiple Myeloma
This pilot early phase I trial studies pembrolizumab in treating patients with slow growing (smoldering) multiple myeloma with intermediate or high-risk of spreading.
- Trial name
- NCT02603887
- Testing
- Laboratory Biomarker Analysis, Pembrolizumab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- M.D. Anderson Cancer Center
Multiple Myeloma
A Study to Evaluate the Safety and Pharmacokinetics of XMAB24306 in Combination With Daratumumab in Participants With Relapsed/Refractory Multiple Myeloma
This study will evaluate the safety, tolerability, pharmacokinetics, and activity of XmAb24306 in combination with a multiple myeloma (MM)-targeting monoclonal antibody capable of inducing antibody-dependent cellular toxicity…
- Trial name
- NCT05243342
- Testing
- XmAb24306, Daratumumab
- Where
- 7 sites in Australia, Denmark and 2 more
- Volunteers
- 18 people
- Sponsor
- Genentech, Inc.
Relapsed/Refractory Multiple Myeloma
A Real-World Observational Study: Zevorcabtagene Autoleucel Injection in Patients with Relapsed/Refractory Multiple Myeloma
This study is a single-arm, open-label, multicenter, post-marketing, Phase IV, prospective, observational clinical trial to evaluate the efficacy and safety of the post-marketing product zevor-cel as treatment for subjects with…
- Trial name
- NCT06659770
- Testing
- Zevorcabtagene Autoleucel
- Volunteers
- 200 people
- Sponsor
- CARsgen Therapeutics Co., Ltd.
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma
Sorafenib in Treating Patients With Metastatic or Unresectable Solid Tumors, Multiple Myeloma, or Non-Hodgkin's Lymphoma With or Without Impaired Liver or Kidney Function
This phase I trial is studying the side effects and best dose of sorafenib in treating patients with metastatic or unresectable solid tumors, multiple myeloma, or non-Hodgkin's lymphoma with or without impaired liver or kidney…
- Conditions
- Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma
- Trial name
- NCT00118170
- Testing
- sorafenib tosylate, pharmacological study
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- National Cancer Institute (NCI)
Lymphoma
Donor T Cells, Low-Dose Aldesleukin, and Low-Dose GM-CSF After Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
RATIONALE: Giving high doses of chemotherapy before a donor stem cell transplant helps stop the growth of cancer cells. It also stops the patient's immune system from rejecting the donor's stem cells.
- Trial name
- NCT00521261
- Testing
- anti-CD3 x anti-CD20 bispecific antibody-armed activated T cells
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Multiple Myeloma
Anlotinib Hydrochloride Capsule Monotherapy and Combination Therapy Relapsed and Refractory Multiple Myeloma
This is a Single-center, Open-label, Single-arm Exploratory Clinical Study to evaluate the safety and efficacy of Anlotinib Hydrochloride Capsule Monotherapy and Combination Therapy in relapsed or refractory multiple myeloma…
- Trial name
- NCT05549973
- Testing
- Anlotinib Hydrochloride Capsule
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Multiple Myeloma
Phase II Study of Lenalidomide/Dexamethasone With or Without Elotuzumab for Newly Diagnosed MM Patients in Japan
The purpose of this study is to determine the efficacy of Lenalidomide/Dexamethasone + Elotuzumab in the subjects with newly diagnosed, previously untreated Multiple Myeloma (MM) in Japan.
- Trial name
- NCT02272803
- Testing
- Lenalidomide, Dexamethasone, Elotuzumab (BMS-901608)
- Where
- 28 sites in Japan
- Volunteers
- 82 people
- Sponsor
- Bristol-Myers Squibb
Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies
RATIONALE: Deferasirox may remove excess iron from the body caused by blood transfusions. PURPOSE: This clinical trial studies deferasirox in treating iron overload caused by blood transfusions in patients with hematologic…
- Conditions
- Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- Trial name
- NCT01273766
- Testing
- deferasirox, laboratory biomarker analysis, enzyme-linked immunosorbent assay
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Wake Forest University Health Sciences
Multiple Myeloma
Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients
The primary objective of this study was to compare progression-free survival in patients with multiple myeloma who relapsed after 1 to 3 prior therapies treated with carfilzomib plus dexamethasone or bortezomib plus dexamethasone.
- Trial name
- ENDEAVOR (NCT01568866)
- Testing
- Carfilzomib, Bortezomib, Dexamethasone
- Where
- 241 sites in United States, Australia and 25 more
- Volunteers
- 929 people
- Sponsor
- Amgen
Chronic Myeloproliferative Disorders, Leukemia
Reduced-Intensity Busulfan and Fludarabine With or Without Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease
RATIONALE: Giving low doses of chemotherapy, such as busulfan and fludarabine, before a donor stem cell transplant helps stop the growth of cancer and abnormal cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00448201
- Testing
- anti-thymocyte globulin, sargramostim, therapeutic allogeneic lymphocytes
- Where
- United States
- Volunteers
- 71 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Multiple Myeloma, Relapse Multiple Myeloma
Study of CAR-BCMA, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against BCMA in Subjects With Multiple Myeloma
This is an open label, abbreviated (3+3) dose escalation study in subjects with RRMM, followed by an extension phase at the selected safe dose.
- Trial name
- NCT05243212
- Testing
- CAR-BCMA
- Where
- Israel
- Volunteers
- 75 people
- Sponsor
- Sheba Medical Center
Relapsed or Refractory Multiple Myeloma
Novel BCMA-targeted CAR-T Cell Therapy for Multiple Myeloma
This study evaluates the safety and efficacy of novel BCMA-targeted CAR-T cell therapy (CBG-002) for patients with relapsed or refractory multiple myeloma (r/r MM).
- Trial name
- NCT04706936
- Testing
- anti-BCMA CAR-T, Cyclophosphamid, Fludarabine
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Multiple Myeloma
BCMA Bispecific Antibody Therapy for Post-BCMA CAR T-Cell Therapy Relapse (RECLAIM)
This is a single-center, single-arm, phase 2 study designed to evaluate the efficacy and safety of linvoseltamab in multiple myeloma (MM) patients who relapsed following BCMA CAR T-cell therapy, whether standard of care or…
- Trial name
- RECLAIM (NCT07009899)
- Testing
- Linvoseltamab
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Medical College of Wisconsin
Cardiac Toxicity, Chemotherapeutic Agent Toxicity
Cardiac Magnetic Resonance Imaging in Patients With Non-Hodgkin Lymphoma or Hodgkin Lymphoma Receiving Doxorubicin
RATIONALE: Diagnostic procedures, such as cardiac magnetic resonance imaging, may help doctors detect early changes in the heart caused by chemotherapy.
- Conditions
- Cardiac Toxicity, Chemotherapeutic Agent Toxicity, Lymphoma
- Trial name
- NCT00577798
- Testing
- contrast-enhanced magnetic resonance imaging
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- University of Nebraska
Multiple Myeloma
Allogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for Relapsed / Progressive Patients With Multiple Myeloma After First-line Therapy
Allogeneic stem cell (allo SCT) transplantation for multiple myeloma is a potential curative treatment, but is associated with morbidity and treatment related mortality.
- Trial name
- AlloRelapseMM (NCT05675319)
- Testing
- Allogeneic Stem Cells, carfilzomib/lenalidomide/dexamethasone (KRD), elotuzumab/lenalidomide/dexamethasone (ERD)
- Where
- 30 sites in Germany
- Volunteers
- 28 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Caregivers of Patients With Multiple Myeloma
Quality of Life Assessment of Caregivers of Patients With Multiple Myeloma
The diagnosis and treatment of multiple myeloma affect not only the patient but also their family and caregivers. Advances in therapy have transformed the follow-up of patients treated for multiple myeloma.
- Trial name
- ENTRAIDANT (NCT07276230)
- Testing
- Therapeutic Education and Needs Assessment Program for Caregivers
- Where
- France
- Volunteers
- 27 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma
This phase I/II trial tests the safety, side effects, best dose, and effectiveness of iberdomide in combination with belantamab mafodotin and dexamethasone in treating patients with multiple myeloma (MM) that has come back after…
- Trial name
- NCT06232044
- Testing
- Iberdomide, Belantamab Mafodotin, Dexamethasone
- Where
- 43 sites in United States
- Volunteers
- 88 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Multiple Myeloma
Lenalidomide and High Dose Melphalan Followed by Autologous Stem Cell Transplant in Multiple Myeloma
This is a research study for newly diagnosed multiple myeloma or multiple myeloma has returned (relapsed). Multiple myeloma is a type of cancer that begins in white blood cells called plasma cells.
- Trial name
- NCT01142232
- Testing
- Lenalidomide plus Melphalan during autologous stem cell transplantation, Lenalidomide maintenance
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Attaya Suvannasankha
Multiple Myeloma
Observational Study to Evaluate the Efficacy and Safety of Bortezomib, Melphalan, Prednisone (VMP) in Participants With Multiple Myeloma
The purpose of this study is to assess the 2-year progression-free survival rate.
- Trial name
- NCT02474563
- Testing
- Bortezomib, Melphalan, Prednisone
- Where
- 18 sites in South Korea
- Volunteers
- 171 people
- Sponsor
- Janssen Korea, Ltd., Korea
Newly Diagnosed Multiple Myeloma
Isatuximab in Combination With Rd Compared to Rd in Elderly Patients (Aged ≥70 Years) With NDMM
As optimal tolerance is the key for developing new treatments for the very elderly population, the aim of the study is to compare the efficacy and tolerance of isatuximab in combination with lenalidomide+dexamethasone (Rd) versus…
- Trial name
- NCT04891809
- Testing
- Isatuximab-Irfc 20 MG/ML [Sarclisa], Lenalidomide, Dexamethasone Oral
- Where
- 14 sites in Austria, Greece and 1 more
- Volunteers
- 198 people
- Sponsor
- Arbeitsgemeinschaft medikamentoese Tumortherapie
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.